Zacks Investment Research
25 Sept 2026, 16:55 UTC · 1h ago
Verdict
Headline takes no side. We score VEEV +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Veeva introduced the Study Builder Agent, an AI-powered tool to accelerate clinical study configuration within its Clinical Data platform.
Newpublished September 25, 2026
So whatBy integrating AI to shorten startup timelines, Veeva aims to lower churn and protect its $43.84 billion market cap via higher switching costs.
More positive than 65% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The Study Builder Agent is bundled into the electronic data capture (EDC) offering with no additional license fee.
Newpublished September 25, 2026
So whatForegoing a standalone fee means no immediate EPS boost, shifting the value driver to long-term retention and platform adoption for FY2027.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company launched a new AI-powered tool designed to improve customer efficiency and strengthen long-term growth and retention.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+1.8%
Price agrees with the score
$279.75 vs $274.84 close before publication (Sep 24) · not market-adjusted
VEEV chart →
